Verified employee & interview reviews

Biocon Reviews

Bengaluru, Karnataka

5.0/ 5

1 review

Biocon Limited is a prominent global biopharmaceutical company headquartered in Bengaluru, India, with its United States headquarters located in Bridgewater, New Jersey. Founded in 1978 by Kiran Mazumdar-Shaw with an initial capital of just ten thousand rupees, the company has grown to become India's largest and most fully integrated, innovation-led biopharmaceutical enterprise. Biocon is driven by a core mission to transform global healthcare access by providing affordable, high-quality, and innovative medicines to patients in over 120 countries, particularly focusing on chronic diseases such as diabetes, oncology, immunology, and autoimmune conditions. The company operates through a well-diversified, vertically integrated business model that spans four key strategic business segments: Generics, Biosimilars, Research Services, and Novel Biologics. The Generics division specializes in manufacturing generic active pharmaceutical ingredients (APIs) and finished generic formulations across therapeutic areas like cardiovascular, anti-diabetics, and multiple sclerosis. In the Biosimilars domain, operated largely through its subsidiary Biocon Biologics, the company is a recognized global pioneer, delivering affordable insulin analogs and monoclonal antibodies for cancer and immunology. The Research Services segment is managed through Syngene International Limited, a publicly traded contract research, development, and manufacturing organization (CRDMO) that supports major global pharmaceutical companies. Biocon operates a highly advanced global infrastructure, encompassing 11 manufacturing locations with more than 215 current Good Manufacturing Practice (cGMP) approvals worldwide, including major facilities in India, Malaysia, and a recently inaugurated manufacturing hub in Cranbury, New Jersey. The company places a heavy emphasis on research and development, maintaining a robust portfolio of over 1,500 patents and consistently ranking among the top global biomanufacturing organizations. Financially, Biocon Limited is publicly listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker BIOCON. For the fiscal year ending March 31, 2025, the company reported a consolidated revenue from operations of INR 16,470 crore, an operating income of INR 4,374 crore, and a net income of INR 1,013 crore. Total corporate assets were valued at INR 58,797 crore. The corporate leadership structure is headed by Kiran Mazumdar-Shaw as the Executive Chairperson, alongside Peter Bains as the Group CEO, Siddharth Mittal as the CEO and Managing Director of the parent company, and Shreehas P. Tambe as the CEO and Managing Director of Biocon Biologics Limited. Moving through 2026, Biocon has finalized the structural integration of its biosimilars and generics businesses into a single unified biopharmaceutical enterprise, focusing its strategic horizon on expanding access to critical treatments like global GLP-1 weight management therapies, driving margin expansion, and creating long-term value.